spironolactone has been researched along with Recrudescence in 31 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
| Excerpt | Relevance | Reference |
|---|---|---|
| "At present, the question of whether radiofrequency ablation (RFA) combined with spironolactone can reduce the levels of plasma angiotensin II (AngII) and aldosterone (ALD) in patients with atrial fibrillation (AF) and reduce the recurrence of AF has not been reported." | 9.41 | Radiofrequency catheter ablation combined with spironolactone in the treatment of atrial fibrillation: A single-center randomized controlled study. ( Chen, J; Chen, L; Chen, Q; Chen, X; Li, J; Sun, X; Wang, W; Xu, Z; Zhang, F, 2021) |
| "To observe the clinical efficacy of Chibixiao Recipe (CBX) in combination with minocycline and spironolactone in treating rosacea in females." | 9.12 | Effect of treatment of rosacea in females by Chibixiao Recipe in combination with minocycline and spironolactone. ( Guo, W; Yu, TG; Zheng, YZ; Zhu, JT, 2006) |
| "Paracentesis is more effective for short-term treatment of ascites but clonidine-spironolactone association might provide better long-term control." | 9.11 | Comparative pilot study of repeated large volume paracentesis vs the combination on clonidine-spironolactone in the treatment of cirrhosis-associated refractory ascites. ( Codden, T; Henry, JP; Legros, F; Lenaerts, A; Ligny, G, 2005) |
| "To compare long-term visual/anatomical outcomes and recurrence rate between oral spironolactone (SPRL) treatment and half-dose photodynamic therapy for nonresolving central serous chorioretinopathy." | 7.96 | COMPARISON OF VISUAL/ANATOMICAL OUTCOMES AND RECURRENCE RATE BETWEEN ORAL SPIRONOLACTONE AND PHOTODYNAMIC THERAPY FOR NONRESOLVING CENTRAL SEROUS CHORIORETINOPATHY. ( Kim, DY; Kim, JY; Lee, EK; Lee, JY, 2020) |
| "To evaluate the effect of eplerenone on patients with long-term recurring central serous chorioretinopathy (CSC)." | 7.83 | Eplerenone in patients with chronic recurring central serous chorioretinopathy. ( Findl, O; Hackl, C; Hirnschall, N; Leisser, C; Plasenzotti, P, 2016) |
| "To present a case of central serous chorioretinopathy (CSC) treatment with spironolactone in a challenge-rechallenge pattern." | 7.81 | Central serous chorioretinopathy treatment with spironolactone: a challenge-rechallenge case. ( Pulido, CM; Ryan, EH, 2015) |
| "We considered that RSD could reduce the recurrence of AF in patients with CKD by modulating sympathetic hyperactivity." | 6.87 | Pulmonary vein isolation combined with spironolactone or renal sympathetic denervation in patients with chronic kidney disease, uncontrolled hypertension, paroxysmal atrial fibrillation, and a pacemaker. ( Chen, S; Hoye, NA; Kiuchi, MG; Pürerfellner, H, 2018) |
| "Retreatment criteria for recurrence were: gain in sub-retinal fluid (SRF) of more than 25 % plus/or increase of central retinal thickness (CRT) of more than 50 μm plus visual symptoms compared to last visit." | 6.84 | Long-term results and recurrence rates after spironolactone treatment in non-resolving central serous chorio-retinopathy (CSCR). ( Herold, TR; Priglinger, SG; Rist, K; Ulbig, MW; Wolf, A, 2017) |
| "At present, the question of whether radiofrequency ablation (RFA) combined with spironolactone can reduce the levels of plasma angiotensin II (AngII) and aldosterone (ALD) in patients with atrial fibrillation (AF) and reduce the recurrence of AF has not been reported." | 5.41 | Radiofrequency catheter ablation combined with spironolactone in the treatment of atrial fibrillation: A single-center randomized controlled study. ( Chen, J; Chen, L; Chen, Q; Chen, X; Li, J; Sun, X; Wang, W; Xu, Z; Zhang, F, 2021) |
| "To observe the clinical efficacy of Chibixiao Recipe (CBX) in combination with minocycline and spironolactone in treating rosacea in females." | 5.12 | Effect of treatment of rosacea in females by Chibixiao Recipe in combination with minocycline and spironolactone. ( Guo, W; Yu, TG; Zheng, YZ; Zhu, JT, 2006) |
| "Paracentesis is more effective for short-term treatment of ascites but clonidine-spironolactone association might provide better long-term control." | 5.11 | Comparative pilot study of repeated large volume paracentesis vs the combination on clonidine-spironolactone in the treatment of cirrhosis-associated refractory ascites. ( Codden, T; Henry, JP; Legros, F; Lenaerts, A; Ligny, G, 2005) |
| "Hirsutism scores decreased significantly and similarly in spironolactone, flutamide, and cyproterone acetate treatment groups." | 5.09 | Recurrence rate of hirsutism after 3 different antiandrogen therapies. ( Durmuşoğlu, F; Erenus, M; Gürbüz, O; Yücelten, D, 1999) |
| "Five patients (three in the placebo and two in the spironolactone group) abandoned the treatment prior to ascites recurrence or the end of the study due to complications or lack of compliance." | 5.08 | Diuretic requirements after therapeutic paracentesis in non-azotemic patients with cirrhosis. A randomized double-blind trial of spironolactone versus placebo. ( Adler, M; Arroyo, V; Elewaut, A; Fernández-Esparrach, G; Geuvel, A; Ginès, P; Guevara, M; Jiménez, W; Lebrec, D; Pardo, A; Planas, R; Sort, P, 1997) |
| "Plasma levels of canrenone and androgen receptor-active materials (ARM) were determined during long-term oral K-canrenoate or spironolactone therapy in cirrhotics with chronic recurrent ascites." | 5.06 | Canrenone and androgen receptor-active materials in plasma of cirrhotic patients during long-term K-canrenoate or spironolactone therapy. ( Andriulli, A; Armanini, D; Arrigoni, A; Buzzetti, G; Gindro, T; Karbowiak, I, 1989) |
| "To compare long-term visual/anatomical outcomes and recurrence rate between oral spironolactone (SPRL) treatment and half-dose photodynamic therapy for nonresolving central serous chorioretinopathy." | 3.96 | COMPARISON OF VISUAL/ANATOMICAL OUTCOMES AND RECURRENCE RATE BETWEEN ORAL SPIRONOLACTONE AND PHOTODYNAMIC THERAPY FOR NONRESOLVING CENTRAL SEROUS CHORIORETINOPATHY. ( Kim, DY; Kim, JY; Lee, EK; Lee, JY, 2020) |
| "To evaluate the effect of eplerenone on patients with long-term recurring central serous chorioretinopathy (CSC)." | 3.83 | Eplerenone in patients with chronic recurring central serous chorioretinopathy. ( Findl, O; Hackl, C; Hirnschall, N; Leisser, C; Plasenzotti, P, 2016) |
| "To present a case of central serous chorioretinopathy (CSC) treatment with spironolactone in a challenge-rechallenge pattern." | 3.81 | Central serous chorioretinopathy treatment with spironolactone: a challenge-rechallenge case. ( Pulido, CM; Ryan, EH, 2015) |
| "In the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) trial, hospitalized AMI patients complicated by left ventricular ejection fraction ≤40% and symptoms of HF receiving standard therapy were randomized 3-14 days post-AMI to receive eplerenone 25-50 mg/day (n = 3319) or placebo (n = 3313)." | 3.77 | Impact of diabetes mellitus on outcomes in patients with acute myocardial infarction and systolic heart failure. ( Aban, IB; Ahmed, A; Ahmed, MI; Deedwania, PC; Feller, MA; Love, TE; Pitt, B, 2011) |
| "We considered that RSD could reduce the recurrence of AF in patients with CKD by modulating sympathetic hyperactivity." | 2.87 | Pulmonary vein isolation combined with spironolactone or renal sympathetic denervation in patients with chronic kidney disease, uncontrolled hypertension, paroxysmal atrial fibrillation, and a pacemaker. ( Chen, S; Hoye, NA; Kiuchi, MG; Pürerfellner, H, 2018) |
| "Retreatment criteria for recurrence were: gain in sub-retinal fluid (SRF) of more than 25 % plus/or increase of central retinal thickness (CRT) of more than 50 μm plus visual symptoms compared to last visit." | 2.84 | Long-term results and recurrence rates after spironolactone treatment in non-resolving central serous chorio-retinopathy (CSCR). ( Herold, TR; Priglinger, SG; Rist, K; Ulbig, MW; Wolf, A, 2017) |
| "Terlipressin has longer effects and is more effective and safer than vasopressin alone or in combination with nitroglycerin." | 2.41 | The sixth Carlos E. Rubio Memorial Lecture. Prevention and treatment of variceal hemorrhage. ( Bosch, J, 2000) |
| "Hyperkalemia is associated with severe clinical outcomes and death in HF." | 1.48 | Elevated Potassium Levels in Patients With Congestive Heart Failure: Occurrence, Risk Factors, and Clinical Outcomes: A Danish Population-Based Cohort Study. ( Adelborg, K; Egfjord, M; Egstrup, K; Garcia-Sanchez, R; Hasvold, P; Nicolaisen, SK; Pedersen, L; Sørensen, HT; Thomsen, RW, 2018) |
| "Our study confirms pregnancy is more difficult to manage at the beginning of MG." | 1.33 | [Myasthenia gravis and pregnancy: clinical course and management of delivery and the postpartum phase]. ( de Seze, J; Defebvre, L; Delalande, S; Delrieu, O; Destée, A; Fourrier, F; Leys, D; Ramirez, C; Stojkovic, T; Vermersch, P, 2006) |
| "Their mitral regurgitation (MR) is a result of left ventricular (LV) geometrical distortion." | 1.33 | Flexible versus nonflexible mitral valve rings for congestive heart failure: differential durability of repair. ( Bolling, SF; Geltz, A; Spoor, MT, 2006) |
| "Ascites in liver cirrhosis is a symptom of advanced liver disease, and liver transplantation should always be considered in eligible patients." | 1.31 | [Therapeutic program for ascites. Recommendations from the Swedish Society of Gastroenterology and Gastrointestinal Endoscopy]. ( Lööf, L; Prytz, H; Söderlund, C; Wallerstedt, S, 2001) |
| "Aldosterone treatment was associated with a decrease in renin activity and a non-significant increase in mean arterial pressure." | 1.29 | Neointimal thickening after balloon denudation is enhanced by aldosterone and inhibited by spironolactone, and aldosterone antagonist. ( Bauters, C; Bertrand, ME; Dupuis, B; Hamon, M; Lablanche, JM; McFadden, EP; Racadot, A; Van Belle, E; Wernert, N, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (22.58) | 18.7374 |
| 1990's | 5 (16.13) | 18.2507 |
| 2000's | 6 (19.35) | 29.6817 |
| 2010's | 10 (32.26) | 24.3611 |
| 2020's | 3 (9.68) | 2.80 |
| Authors | Studies |
|---|---|
| Tanaka, S | 1 |
| Imamura, T | 1 |
| Ueno, H | 1 |
| Kinugawa, K | 1 |
| Wang, W | 1 |
| Chen, Q | 1 |
| Zhang, F | 1 |
| Chen, X | 1 |
| Xu, Z | 1 |
| Sun, X | 1 |
| Li, J | 1 |
| Chen, L | 1 |
| Chen, J | 1 |
| Kiuchi, MG | 1 |
| Chen, S | 1 |
| Hoye, NA | 1 |
| Pürerfellner, H | 1 |
| Thomsen, RW | 1 |
| Nicolaisen, SK | 1 |
| Hasvold, P | 1 |
| Garcia-Sanchez, R | 1 |
| Pedersen, L | 1 |
| Adelborg, K | 1 |
| Egfjord, M | 1 |
| Egstrup, K | 1 |
| Sørensen, HT | 1 |
| Kim, DY | 1 |
| Lee, JY | 1 |
| Lee, EK | 1 |
| Kim, JY | 1 |
| Ryan, EH | 1 |
| Pulido, CM | 1 |
| Leisser, C | 1 |
| Hirnschall, N | 1 |
| Hackl, C | 1 |
| Plasenzotti, P | 1 |
| Findl, O | 1 |
| Herold, TR | 1 |
| Rist, K | 1 |
| Priglinger, SG | 1 |
| Ulbig, MW | 1 |
| Wolf, A | 1 |
| Tsuda, E | 1 |
| Matsuo, M | 1 |
| Sakaguchi, H | 1 |
| Hayashi, T | 1 |
| Hosoda, K | 1 |
| Miyazaki, A | 1 |
| Olowu, WA | 1 |
| Adelusola, KA | 1 |
| Adefehinti, O | 1 |
| Sundar, U | 1 |
| Lakkas, Y | 1 |
| Asole, D | 1 |
| Vaidya, M | 1 |
| Deedwania, PC | 1 |
| Ahmed, MI | 1 |
| Feller, MA | 1 |
| Aban, IB | 1 |
| Love, TE | 1 |
| Pitt, B | 1 |
| Ahmed, A | 1 |
| Carrascosa, MF | 1 |
| Larroque, IC | 1 |
| Rivero, JL | 1 |
| García, JA | 1 |
| Hoz, MC | 1 |
| Ares, MA | 1 |
| López, XA | 1 |
| Caviedes, JR | 1 |
| Lenaerts, A | 1 |
| Codden, T | 1 |
| Henry, JP | 1 |
| Legros, F | 1 |
| Ligny, G | 1 |
| Ramirez, C | 1 |
| de Seze, J | 1 |
| Delrieu, O | 1 |
| Stojkovic, T | 1 |
| Delalande, S | 1 |
| Fourrier, F | 1 |
| Leys, D | 1 |
| Defebvre, L | 1 |
| Destée, A | 1 |
| Vermersch, P | 1 |
| Spoor, MT | 1 |
| Geltz, A | 1 |
| Bolling, SF | 1 |
| Yu, TG | 1 |
| Zheng, YZ | 1 |
| Zhu, JT | 1 |
| Guo, W | 1 |
| Kesler, DF | 1 |
| Van Belle, E | 1 |
| Bauters, C | 1 |
| Wernert, N | 1 |
| Hamon, M | 1 |
| McFadden, EP | 1 |
| Racadot, A | 1 |
| Dupuis, B | 1 |
| Lablanche, JM | 1 |
| Bertrand, ME | 1 |
| Fernández-Esparrach, G | 1 |
| Guevara, M | 1 |
| Sort, P | 1 |
| Pardo, A | 1 |
| Jiménez, W | 1 |
| Ginès, P | 1 |
| Planas, R | 1 |
| Lebrec, D | 1 |
| Geuvel, A | 1 |
| Elewaut, A | 1 |
| Adler, M | 1 |
| Arroyo, V | 1 |
| Yücelten, D | 1 |
| Erenus, M | 1 |
| Gürbüz, O | 1 |
| Durmuşoğlu, F | 1 |
| Bosch, J | 1 |
| Lööf, L | 1 |
| Prytz, H | 1 |
| Söderlund, C | 1 |
| Wallerstedt, S | 1 |
| Chan, MK | 1 |
| Sweny, P | 1 |
| Varghese, Z | 1 |
| Fernando, ON | 1 |
| Moorhead, JF | 1 |
| Hagège, H | 1 |
| Ink, O | 1 |
| Ducreux, M | 1 |
| Pelletier, G | 1 |
| Buffet, C | 1 |
| Etienne, JP | 1 |
| Gentilini, P | 1 |
| Andriulli, A | 2 |
| Arrigoni, A | 2 |
| Gindro, T | 2 |
| Karbowiak, I | 1 |
| Buzzetti, G | 1 |
| Armanini, D | 1 |
| Callan, AW | 1 |
| Verme, G | 1 |
| Marcos Sánchez, F | 1 |
| Aguirre de Cárcer, A | 1 |
| Durán Pérez-Navarro, A | 1 |
| Olbing, H | 1 |
| Greifer, I | 1 |
| Bennett, BP | 1 |
| Bernstein, J | 1 |
| Spitzer, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Non-Responsive Diabetic Macular Edema in Patients With Pachychoroid and Choroidal Hyperpermeability.[NCT04853355] | Phase 4 | 0 participants (Actual) | Interventional | 2022-07-31 | Withdrawn (stopped due to lack of funding) | ||
| The Effects of Clonidine on the Diuretic Response in Cirrhotic Patients With Ascites and Activation of Sympathetic Nervous System: a Randomized Double-Blind Placebo Controlled Study.[NCT00356226] | 64 participants | Interventional | 2000-10-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for spironolactone and Recrudescence
| Article | Year |
|---|---|
The sixth Carlos E. Rubio Memorial Lecture. Prevention and treatment of variceal hemorrhage.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Double-Blind Method; Drug Therapy, Combination | 2000 |
Spironolactone therapy in hirsutism and acne.
Topics: Acne Vulgaris; Androgens; Drug Administration Schedule; Female; Hirsutism; Humans; Recurrence; Spiro | 1988 |
10 trials available for spironolactone and Recrudescence
| Article | Year |
|---|---|
Radiofrequency catheter ablation combined with spironolactone in the treatment of atrial fibrillation: A single-center randomized controlled study.
Topics: Atrial Fibrillation; Catheter Ablation; Heart Atria; Humans; Pulmonary Veins; Recurrence; Spironolac | 2021 |
Pulmonary vein isolation combined with spironolactone or renal sympathetic denervation in patients with chronic kidney disease, uncontrolled hypertension, paroxysmal atrial fibrillation, and a pacemaker.
Topics: Aged; Atrial Fibrillation; Catheter Ablation; Combined Modality Therapy; Double-Blind Method; Echoca | 2018 |
Long-term results and recurrence rates after spironolactone treatment in non-resolving central serous chorio-retinopathy (CSCR).
Topics: Central Serous Chorioretinopathy; Choroid; Female; Fluorescein Angiography; Follow-Up Studies; Fundu | 2017 |
Comparative pilot study of repeated large volume paracentesis vs the combination on clonidine-spironolactone in the treatment of cirrhosis-associated refractory ascites.
Topics: Adrenergic alpha-Agonists; Ascites; Clonidine; Diuretics; Drug Resistance; Drug Therapy, Combination | 2005 |
Effect of treatment of rosacea in females by Chibixiao Recipe in combination with minocycline and spironolactone.
Topics: Adult; Drug Therapy, Combination; Female; Humans; Medicine, Chinese Traditional; Middle Aged; Minocy | 2006 |
Diuretic requirements after therapeutic paracentesis in non-azotemic patients with cirrhosis. A randomized double-blind trial of spironolactone versus placebo.
Topics: Aldosterone; Ascites; Combined Modality Therapy; Diuretics; Dose-Response Relationship, Drug; Double | 1997 |
Recurrence rate of hirsutism after 3 different antiandrogen therapies.
Topics: Androgen Antagonists; Contraceptives, Oral; Cyproterone; Female; Flutamide; Hirsutism; Humans; Lutei | 1999 |
[Treatment of ascites in patients with liver cirrhosis without neither hyponatremia nor renal insufficiency. Results of a randomized study comparing diuretics and punctures compensated by albumin].
Topics: Aged; Albumins; Ascites; Combined Modality Therapy; Drug Therapy, Combination; Female; Furosemide; H | 1992 |
Canrenone and androgen receptor-active materials in plasma of cirrhotic patients during long-term K-canrenoate or spironolactone therapy.
Topics: Adult; Aged; Ascites; Canrenoic Acid; Canrenone; Chronic Disease; Clinical Trials as Topic; Double-B | 1989 |
The use of diuretics in preventing ascites recurrence.
Topics: Adult; Aged; Ascites; Canrenoic Acid; Follow-Up Studies; Humans; Liver Cirrhosis; Male; Middle Aged; | 1988 |
19 other studies available for spironolactone and Recrudescence
| Article | Year |
|---|---|
MitraClip or Ventricular Assist Device?
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cardiac Resynchronization The | 2020 |
Elevated Potassium Levels in Patients With Congestive Heart Failure: Occurrence, Risk Factors, and Clinical Outcomes: A Danish Population-Based Cohort Study.
Topics: Aged; Aged, 80 and over; Biomarkers; Denmark; Female; Heart Failure; Humans; Hyperkalemia; Incidence | 2018 |
COMPARISON OF VISUAL/ANATOMICAL OUTCOMES AND RECURRENCE RATE BETWEEN ORAL SPIRONOLACTONE AND PHOTODYNAMIC THERAPY FOR NONRESOLVING CENTRAL SEROUS CHORIORETINOPATHY.
Topics: Administration, Oral; Central Serous Chorioretinopathy; Female; Fluorescein Angiography; Fundus Ocul | 2020 |
Central serous chorioretinopathy treatment with spironolactone: a challenge-rechallenge case.
Topics: Adult; Central Serous Chorioretinopathy; Humans; Male; Mineralocorticoid Receptor Antagonists; Recur | 2015 |
Eplerenone in patients with chronic recurring central serous chorioretinopathy.
Topics: Aged; Central Serous Chorioretinopathy; Chronic Disease; Eplerenone; Female; Fluorescein Angiography | 2016 |
Combined amiodarone and low-dose carvedilol treatment for severe heart failure in childhood.
Topics: Adolescent; Amiodarone; Anti-Arrhythmia Agents; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Dos | 2010 |
Childhood idiopathic steroid resistant nephrotic syndrome in Southwestern Nigeria.
Topics: Adolescent; Angiotensin-Converting Enzyme Inhibitors; Child; Child, Preschool; Cyclophosphamide; Dex | 2010 |
Gitelman's syndrome presenting as recurrent paralytic ileus due to chronic renal tubular K+ wasting.
Topics: Alkalosis; Bartter Syndrome; Calcium; Chronic Disease; Diagnosis, Differential; Diuretics; Gitelman | 2010 |
Impact of diabetes mellitus on outcomes in patients with acute myocardial infarction and systolic heart failure.
Topics: Aged; Diabetic Angiopathies; Eplerenone; Female; Heart Failure; Humans; Male; Middle Aged; Mineraloc | 2011 |
Pulmonary arterial hypertension associated with neurofibromatosis type 1.
Topics: Aged; Anticoagulants; Combined Modality Therapy; Diuretics; Dyspnea; Fatal Outcome; Female; Follow-U | 2010 |
[Myasthenia gravis and pregnancy: clinical course and management of delivery and the postpartum phase].
Topics: Abortion, Therapeutic; Adult; Autoantibodies; Autoantigens; Cholinesterase Inhibitors; Delivery, Obs | 2006 |
Flexible versus nonflexible mitral valve rings for congestive heart failure: differential durability of repair.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiomyopathy, Dilated; Combined Modality | 2006 |
[Prevention of frequent paroxysmal ventricular tachycardia by combined use of anti-arrhythmia drugs].
Topics: Aged; Alprenolol; Anti-Arrhythmia Agents; Drug Therapy, Combination; Humans; Lanatosides; Male; Midd | 1981 |
Neointimal thickening after balloon denudation is enhanced by aldosterone and inhibited by spironolactone, and aldosterone antagonist.
Topics: Aldosterone; Angioplasty, Balloon; Animals; Aorta; Blood Pressure; Coronary Disease; Iliac Artery; R | 1995 |
[Therapeutic program for ascites. Recommendations from the Swedish Society of Gastroenterology and Gastrointestinal Endoscopy].
Topics: Ascites; Contraindications; Diuretics; Furosemide; Humans; Liver Cirrhosis; Paracentesis; Peritoneov | 2001 |
Diuretic escape and rebound oedema in renal allograft recipients.
Topics: Edema; Furosemide; Graft Rejection; Humans; Kidney Transplantation; Recurrence; Spironolactone; Tran | 1979 |
Spironolactone and canrenoate: different antialdosteronic diuretic agents.
Topics: Ascites; Canrenoic Acid; Canrenone; Humans; Liver Cirrhosis; Recurrence; Spironolactone | 1991 |
[Upper digestive hemorrhage caused by recurrent gastritis. Adverse effects of spironolactone].
Topics: Aged; Gastritis; Gastrointestinal Hemorrhage; Humans; Male; Recurrence; Spironolactone | 1985 |
Idiopathic membranous nephropathy in children.
Topics: Adolescent; Age Factors; Aminohippuric Acids; Basement Membrane; Biopsy; Child; Child, Preschool; Cr | 1973 |